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Autism spectrum disorder (ASD) is an increasingly prevalent neurodevelopmental condition of unknown etiology. Mercury is a common, 
highly neurotoxic heavy metal. The similarities of neurologic manifestations of mercury exposure and ASD raise an intriguing hypothetical 
question: Is ASD, at least partially, a manifestation of mercury toxicity? The fetus is particularly vulnerable to mercury exposure from the 
“double jeopardy” combination of the genetics of his mother and his own genetics, as relates to mercury toxicity. In this paper, I review 
the evidence suggesting relationships between ASD and mercury toxicity. I suggest ways to confirm these relationships with genetic and 
epigenetic research. I propose a hypothesis associating mercury toxicity with ASD. This may present opportunities for further research 
in prevention and treatment of ASD.
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INTRODUCTION
Autism spectrum disorder (ASD) is an increasing‑
ly prevalent neurodevelopmental condition of un‑
known etiology. Importantly, reported manifestations 
of low‑level exposure to mercury, a highly neurotox‑
ic heavy metal, are similar to those of ASD. In the past 
several years, evidence has accumulated linking the risk 
of toxic manifestations of low‑level mercury exposure 
to particular genes, mutations, and epigenetic chang‑
es. The fields of genomics, genetics, and epigenetics are 
rapidly developing, which has led to the creation of new 
methods and tools that can be applied to investigate her‑
itable conditions and diseases. These methods and tools 
are particularly well suited for seeking genetic predis‑
positions to toxicity from exposures and adverse mani‑
festations of those exposures, such as mercury and ASD. 
In the present paper, we examine the evidence linking 
ASD with mercury toxicity. We present a plausible etio‑
logic mechanism of ASD causation, consisting of prena‑
tal mercury exposure together with maternal and fetal 
genetic propensities, causing an elevated risk of subse‑
quent neurotoxicity via a “double jeopardy”. This anal‑
ysis will suggest means of confirming or refuting rela‑
tionships between mercury exposure and ASD through 
targeted clinical investigations that utilize these new 
genomic, genetic, and epigenetic methods and tools.
In various degrees of severity, ASD has been recog‑
nized for three quarters of a century as a constellation 
of neurologically debilitating symptoms in children. 
These symptoms begin in infancy or early childhood 
and progress through adulthood (Kanner, 1995). ASD in‑
cludes various manifestations of neurologic symptoms 
and findings, with specific identifiable characteristics 
and various degrees of severity. ASD has been previously 
known as autism, Asperger’s syndrome, childhood disin‑
tegrative disorder, and pervasive developmental disor‑
der. Despite the large body of peer reviewed publications 
on ASD, a paradigm that explains the well described clin‑
ical findings of ASD is lacking. 
Received 21 September 2018, accepted 5 April 2019
REVIEW
Acta Neurobiol Exp 2019, 79: 113–125
DOI: 10.21307/ane‑2019‑010
114 M.E. McCaulley Acta Neurobiol Exp 2019, 79: 113–125
Mercury is a markedly toxic metal that is prevalent 
in our environment as a result of both natural process‑
es and human activity. A number of factors have point‑
ed to a potential role of mercury in ASD. Some of these 
factors are:  
1) The marked similarity of manifestations of mercury 
toxicity and of ASD.
2) The ubiquity of exposure to mercury.
3) The increasing prevalence and incidence of ASD, at 
a time when exposure to mercury and its presence 
in the environment have shown similar increases.
4) The large number of peer reviewed papers published 
in the scientific literature demonstrating plausible 
and logical means and mechanisms that implicate 
a causal role for mercury in ASD.
5) The lack, at this time, of a competing etiologic agent 
or mechanism supporting a paradigm that explains 
the ultimate cause of ASD.
6) The Apolipoprotein E (ApoE) system being linked 
with both mercury toxicity and ASD.
7) Genomic studies which account for observations 
that similar levels of mercury affect different peo‑
ple to different degrees. 
It is important to recognize the confounding role 
that economic, emotional, and social factors play in 
evaluating the role of mercury as an important poten‑
tial cause of ASD. These potential confounding roles 
are exacerbated by the key role that mercury plays in 
industry, pharmaceuticals, dentistry, and medicine. 
If mercury were to be established as a dangerous sub‑
stance in our environment, even at tiny doses, the costs 
involved in its elimination would be economically chal‑
lenging to bear. The devastating consequences of ASD to 
patients, families, and society at large are likewise cata‑
strophic and not bearable if there is any way to mitigate 
or avoid them. The presence of a ‑ by some estimates 
‑ likely etiologic factor in ASD necessitates action to 
identify and combat that factor. It is the responsibility 
of the scientific community at large to reject economic, 
emotional, and social influences and to proceed in an 
evidence‑based manner in the search for truth. 
It is widely recognized that younger, more rapidly 
developing brains are more vulnerable to toxic expo‑
sures, particularly to mercury exposure (Hewitson et 
al., 2010; Ida‑Eto et al., 2011; Olczak et al., 2011; Sulkow‑
ski et al., 2012; Blanusa et al., 2012; Ida‑Eto et al., 2013). 
In a 1997 publication, Grandjean et al. note that prena‑
tal exposure to methylmercury is associated with sig‑
nificant detectable neurologic performance deficits at 
age 7, as measured via neuropsychological evaluation. 
These neurologic deficits are observed in the domains 
of language, attention, memory, visuospatial and motor 
functions. Of note, levels of mercury exposure in that 
study were of a degree that is considered safe (Grand‑
jean et al., 1997). Later, in a 2006 paper, Grandjean et al. 
summarize the toxicities of mercury and other indus‑
trial chemicals, noting their propensities to cause neu‑
rodevelopmental disorders. Also noted is the greatly 
increased hazard of these agents for developing brains, 
both in utero and in early childhood (Grandjean and 
Landrigan, 2006). In one study, in a population with low 
prenatal degrees of mercury exposure, there was none‑
theless a mercury‑related IQ decrement with higher 
levels of mercury exposure. However, this effect was 
observed only in the higher socio‑economic segment of 
the population. In addition, genetic polymorphisms in 
children contributed to neurotoxic effects of mercury, 
although these effects were mild (Julvez et al., 2013). 
Another more recent study showed adverse motor out‑
comes at age 2 years that were related to prenatal mer‑
cury exposure. In that study, genetic predisposition for 
mercury toxicity or ASD risk was not assessed (Barbone 
et al., 2019). In a 2017 study, Prpic et al. reported a dec‑
rement in fine motor skills at age 18 months in subjects 
who had increased prenatal methylmercury exposure, 
as measured via cord blood methylmercury levels. Ge‑
netic risk for mercury toxicity was not evaluated in 
that study (Prpic et al., 2017).
A considerable number of papers have reported ev‑
idence suggesting that mercury toxicity is a cause of 
ASD manifestations. In a 2001 publication, Bernard et 
al., articulated the similarities between mercury tox‑
icity and ASD manifestations. These authors conclud‑
ed that “autism represents an unrecognized mercurial 
syndrome”. In this paper, the authors also present evi‑
dence for thimerosal as a source for the brain damaging 
mercury (Bernard et al., 2001). Table II in the Bernard 
et al. (2001) paper (presented here, as Table I, with per‑
mission) summarizes those similarities.  
In 2004, Geier and Geier evaluated epidemiologi‑
cal data from the US Centers for Disease Control and 
Prevention (CDC) and datasets from US Department of 
Education datasets. The authors demonstrated a cor‑
relation between higher mercury exposure through 
vaccine use, and an increasing incidence of ASDs. Based 
on these data, the authors claim that “there is biolog‑
ical plausibility and epidemiological evidence showing 
a direct relationship between increasing doses of mer‑
cury from Thimerosal‑containing vaccines and neuro‑
developmental disorders” (Geier and Geier, 2004).
Multiple studies have found evidence of abnormal 
oxidation, impaired methylation, and enzymatic dys‑
function in ASD populations. In a 2004 publication, 
James et al. reported impaired methylation and in‑
creased oxidative stress in a cohort of 20 children with 
autism compared to 33 control children. The authors 
note that these metabolic abnormalities may contrib‑
ute to the manifestation of autism (James et al., 2004). 
ASD and mercury toxicity 115Acta Neurobiol Exp 2019, 79: 113–125
Importantly, these metabolic abnormalities are similar 
to those of mercury toxicity. In a 2006 report, James et 
al. again noted that methylation capacity was reduced 
in autistic children, based on the ratio of S‑adenosylme‑
thionine to S‑adenosylhomocysteine. Antioxidant ca‑
pacity and redox homeostasis were likewise decreased 
based on levels of cysteine, glutathione, and oxidized 
glutathione. A variety of allele frequencies and poly‑
morphisms were noted in relevant genes that would be 
expected to impact these capabilities. The authors not‑
ed “that an increased vulnerability to oxidative stress 
(endogenous or environmental) may contribute to the 
Table I. Summary comparison of biological abnormalities in autism and mercury exposure. 
Mercury exposure Autism
Biochemistry
Binds ‑SH groups; blocks sulfate transporter in intestines and kidneys
Reduces glutathione availability; inhibits enzymes of glutathione 
metabolism; glutathione is needed in neurons, cells, and liver to detoxify 
heavy metals; reduces glutathione peroxidase and reductase
Disrupts purine and pyrimidine metabolism
Disrupts mitochondrial activities, especially in brain
Low sulfate levels
Low levels of glutathione; decreased ability of liver to detoxify 
xenobiotics; abnormal glutathione peroxidase activity in erythrocytes
Purine and pyrimidine metabolism errors lead to autistic features
Mitochondrial dysfunction, especially in brain
Immune system
Sensitive individuals more likely to have allergies, asthma, and 
autoimmune‑like symptoms (particularly rheumatoid‑like ones)
Can produce an immune response in CNS; causes brain/MBP 
autoantibodies
Causes overproduction of Th2 subset; kills/inhibits lymphocytes, T‑cells, 
and monocytes; decreases NK T‑cell activity; induces or suppresses IFNg 
& IL‑2
More likely to have allergies and asthma; familial presence of 
autoimmune diseases (particularly rheumatoid arthritis); lgA deficiencies
Ongoing immune response in CNS; brain/MBP autoantibodies present
Skewed immune‑cell subset in the Th2 direction; decreased responses to 
T‑cell reduced NK T‑cell function; increased IFNg & IL‑12
CNS structure
Selectively targets brain areas that are unable to detoxify or reduce 
Hg‑induced oxidative stress
Accumulates in amygdala, hippocampus, basal ganglia, cerebral cortex; 
damages Purkinje and granule cells in cerebellum; brain stem defects in 
some cases
Causes abnormal neuronal cytoarchitecture; disrupts neuronal 
migration, microtubules, and cell division; reduces NCAMs
Progressive microcephaly
Specific areas of brain pathology; many functions spared
Pathology in amygdala, hippocampus, basal ganglia, cerebral cortex; 
damage to Purkinje and granule cells in cerebellum; brain stem defects 
in some cases
Neuronal disorganization; increased neuronal cell replication increased 
glial cells; depressed expression of NCAMs
Progressive microcephaly and macrocephaly
Neurochemistry
Prevents presynaptic serotonin release and inhibits serotonin transport; 
causes calcium disruptions
Alters dopamine systems; pyridoxine deficiency in rats resembles 
mercurialism in humans
Elevates epinephrine and norepinephrine levels by blocking enzyme that 
degrades epinephrine
Elevates glutamate
Leads to cortical acetylcholine deficiency; increases muscarinic receptor 
density in hippocampus and cerebellum
Causes demyelinating neuropathy
Decreased serotonin synthesis in children; abnormal calcium 
metabolism
Either high or low dopamine levels; positive response to pyridoxine, 
which lowers dopamine levels. Elevated norepinephrine and epinephrine
Elevated glutamate and aspartate
Cortical acetylcholine deficiency; reduced muscarinic receptor binding in 
hippocampus
Demyelination in brain
Neurophysiology
Causes abnormal EEGs, epileptiform activity, variable patterns,
e.g., subtle, low amplitude seizure activities
Causes abnormal vestibular nystagmus responses; loss of sense of 
position in space
Results in autonomic disturbance: excessive sweating, poor circulation, 
elevated heart rate
Abnormal EEGs, epileptiform activity, variable patterns, including subtle, 
low amplitude seizure activities
Abnormal vestibular nystagmus responses; loss of sense of position in 
space
Autonomic disturbance: unusual sweating, poor circulation, elevated 
heart rate
Reprinted with permission: Bernard et al. (2001) Autism: a novel form of mercury poisoning. Med Hypotheses 56: 462‑471.
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development and clinical manifestations of autism” 
(James et al., 2006).
Several authors have reported associations among 
mercury exposure, elevated levels of mercury in in‑
dividuals, or definite mercury toxicity in ASD pop‑
ulations. In a 2006 paper, Monnet‑Tschudi et al. not‑
ed that heavy metal concentrations caused delayed 
toxicity in an animal model. The authors stated that 
“heavy metals lead and mercury contribute to the eti‑
ology of neurodegenerative diseases and emphasize 
the importance of taking preventive measures in this 
regard” (Monnet‑Tschudi et al., 2006). Also in a 2006 
study, Palmer et al. found significantly increased rates 
of ASD in geographic areas with higher levels of mercu‑
ry released into the environment. The authors’ conclu‑
sion was carefully worded: “These results have implica‑
tions for policy planning and cost analysis” (Palmer et 
al., 2006). Eliminating the environmental emissions of 
mercury could prove economically challenging.
In a 2008 study, Adams et al. compared mercury 
levels in the baby teeth of ASD children and controls. 
The authors found that ASD children had 2.1 times the 
level of mercury in their teeth compared to controls. 
Children with ASD also had used significantly more 
antibiotics in their first 12 months of life as compared 
to controls (Adams et al., 2007). In 1981, Seko et al. re‑
ported mechanisms by which antibiotics lead to signif‑
icant reductions in excretion of mercury administered 
to mice. Excretion of inorganic mercury was reduced 
to 26% of control levels in mice given antibiotics, and 
total mercury excretion was reduced to 60% of control 
levels (Seko et al., 1981). Mice fed a synthetic diet com‑
pared to a milk‑based diet were less able to excrete mer‑
cury (Rowland et al., 1984). In each case, the authors 
hypothesized that it was the impact of antibiotics and/
or a less appropriate food source on the mouse intesti‑
nal microbiome that led to adverse changes in mercu‑
ry excretion. In 2007, Desoto and Hitlan also reported 
a significant relationship between higher blood levels 
of mercury and ASD. This paper also reported reduced 
excretion of mercury in hair, suggesting impaired mer‑
cury excretion in ASD (Desoto and Hitlan, 2007).
In 2009, Adams et al., reported a correlation be‑
tween the severity of ASD symptoms and the body bur‑
den of toxic metals. Dental amalgams were reported‑
ly associated with ASD in a 2009 study. In that study, 
pregnant women with more than 6 dental amalgams 
were found to be 3.2‑fold more likely to have a child 
with ASD than those women with five or fewer amal‑
gams (Geier et al., 2009).
In a 2010 study, Geier et al. reported an analysis 
of red blood cell (RBC) mercury levels in ASD versus 
normal subjects. The authors found that RBC mercury 
levels were 1.9‑fold higher in ASD subjects than in the 
control group. The authors further tested the data for 
a threshold that would indicate toxic mercury levels. 
They found that subjects with an RBC mercury level 
of 15 microgram/liter had a 6.4 times greater risk of 
being diagnosed with an ASD (P<0.0005) than subjects 
with an RBC mercury level less than 15 micrograms per 
liter. The authors stated that “the weight of scientific 
evidence supports Hg as a causal factor in subjects di‑
agnosed with an ASD” (Geier et al., 2010).
In a study published in 2011, Garrecht and Aus‑
tin evaluated the possibility that mercury is involved 
in the etiology of autism. The authors conclude: “the 
existing scientific literature supports the biological 
plausibility of a Hg‑based autism pathogenesis”. This 
comprehensive, well‑referenced paper also discuss‑
es genetic propensities that would be expected to in‑
crease risk of mercury‑associated neurodegenerative 
disease (Garrecht and Austin, 2011). In the same year, 
Lakshmi Priya and Geetha examined hair and nail levels 
of mercury and lead levels, as well as, levels of essen‑
tial metals in hair and nails of ASD subjects ages 4‑12. 
The authors found that levels of mercury, lead, and 
also copper were elevated in ASD subjects compared to 
controls. The more severely symptomatic ASD subjects 
had more marked mercury and lead elevations (Laksh‑
mi Priya and Geetha, 2011). Also in 2011, Thomas Cur‑
tis et al. reported that mercury induced an increase 
in tumor necrosis factor (TNF‑α) in the hippocampus 
and cerebellum in male (but not female) prairie voles. 
In addition to providing support for mercury induced 
neurodegenerative diseases in general, this study of‑
fers potential insight into the observation of male pre‑
ponderance in ASD (Thomas Curtis et al., 2011).
Genetics
Genetic factors underlie an individual’s vulnerabil‑
ity to the toxic effects of mercury (Gundacker et al., 
2010: Llop et al., 2014; Andreoli and Sprovieri, 2017; 
Llop et al., 2017). The incorporation of newer genetic 
(or genomic) and epigenetic insights into theories of 
causation of neurodevelopmental disease constitutes 
an important means to more fully understand the fun‑
damental etiologies of these conditions. A number of 
genetic factors influencing mercury toxicity and risk of 
ASD have been, and continue to be, reported (Spalletta 
et al., 2007; Goodrich et al., 2011; Austin et al., 2014; 
Drescher et al., 2014; Engstrom et al., 2016; Parajuli et 
al., 2016; Spencer et al., 2018). ASD risk has a strong 
genetic component. The majority of investigators esti‑
mate that 38‑90% of ASD risk arises from genetic com‑
ponents, and the remaining risk comes from unknown 
environmental factors. Consistent with the “double 
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jeopardy” of fetal genetic risk (see below), maternal 
inheritance appears stronger than that derived from 
paternal inheritance (Sandin et al., 2014; 2017; Yip et 
al., 2018).
The goal of the Casa Pia Children’s Amalgams clini‑
cal trial was to evaluate risk of mercury exposure from 
dental amalgams in children. Results of the trial showed 
no overall deficit attributable to dental amalgams. How‑
ever, genomic analyses linked several genetic polymor‑
phisms to significantly increased toxicity from higher 
mercury levels, particularly in boys. Variant genotypes 
in 12 of the 13 identified genes were found to impart 
detriments in neurobehavioral outcomes. This major 
prospective study establishes links between risks of 
mercury toxicity and specific genes and gene variants. 
The authors stated that the mercury sources impart‑
ing the noted risks are largely from seafood, with only 
a small portion of the mercury exposure coming from 
amalgams (Woods et al., 2012; 2013; 2014).
In a 2017 report, Andreoli and Sprovieri discuss the 
increased vulnerability of children to the toxic effects 
of mercury. The authors note variable toxic manifesta‑
tions in individuals who are exposed to the same level 
of mercury:  “There exists a marked variability of per‑
sonal response to detrimental mercury action”. Fur‑
ther, the authors note that “new scientific evidence on 
genetic backgrounds has raised the issue of whether 
candidate susceptibility genes can make certain indi‑
viduals more or less vulnerable to mercury toxicity.” In 
their paper, the authors present a detailed assessment 
of multiple gene polymorphisms that would be expect‑
ed to influence vulnerability to mercury exposure, call‑
ing these risk influencing genes “candidate suscepti‑
bility genes”.
ApoE
Apolipoproteins are glycoprotein components of li‑
poproteins, such as chylomicrons, LDL, and HDL. Apo‑
lipoproteins solubilize and facilitate the transport of 
lipids in plasma (Vance and Hayashi, 2010). One type of 
apolipoprotein, ApoE, regulates brain lipid metabolism 
and modulates the delivery of cholesterol to neurons 
and to the brain more generally. The brain is an organ 
with the highest cholesterol content in the human body, 
and ApoE is the most prominent apolipoprotein in the 
brain. The brain synthesizes ApoE and utilizes it for 
growth and remodeling (Hirsch‑Reinshagen et al., 2009). 
ApoE consists of 299 amino acids, and exists in three 
isoforms with variation in amino acids at positions 112 
and 158. ApoE2 has cysteine (i.e., sulfur containing) 
amino acids at both positions, ApoE4 has arginine ami‑
no acids (non‑sulfur containing) at both positions, and 
ApoE3 has a cysteine amino acid at position 112 and an 
arginine at 158 (Arrifano et al., 2018).
The ApoE system in the body is the most significant 
heritable factor known to confer risk of, or resistance to, 
Alzheimer’s disease. Humans have two ApoE alleles, and 
these alleles can be either ApoE2, ApoE3, or ApoE4. One 
copy of each allele is inherited from each parent. The 
highest risk of Alzheimer’s disease (and possibly ASD 
and mercury toxicity, as we describe below) is found in 
people with two ApoE4 alleles. The lowest risk, in con‑
trast, is associated with two ApoE2 alleles and other 
ApoE combinations denote intermediate risk (Mutter 
et al., 2004). The body utilizes sulfur containing amino 
acids in detoxification pathways. Given that less detoxi‑
fication capability would be expected in ApoE4 carriers 
due to the lack of sulfhydryl groups, deficient detoxi‑
fication of heavy metals and other toxins is a plausible 
explanation for the ApoE‑associated Alzheimer’s dis‑
ease (and possibly ASD and mercury risk characteris‑
tics) (Godfrey et al., 2003; Mutter et al., 2007).
Recent data indicate increased risk of toxicity from 
mercury in ApoE4 allele carriers (Arrifano et al., 2018). 
ApoE4 carriers were noted to have a higher risk of a va‑
riety of ASD‑like abnormalities in neurodevelopment 
and emotional well‑being in childhood. Impaired mer‑
cury detoxification would be anticipated and has been 
shown in individuals with two ApoE4 alleles (Ng et al., 
2013; 2015). Increased prenatal exposure to mercury 
was shown to increase risks of adverse findings in cog‑
nitive and fine motor skills at 18 months of age, but 
only in ApoE4 carriers (Snoj Tratnik et al., 2017). On 
the other hand, no adverse impact of ApoE4 alleles on 
incidence of ASD was found in a 2004 study of over 300 
ASD families (Raiford et al., 2004). 
In a related recent study, ApoE hypermethylation 
was noted to be a risk factor for ASD in a Chinese pop‑
ulation. Hypermethylation, an epigenetic marker, was 
associated with decreased levels of ApoE (Hu et al., 
2018). This finding adds credence to the previously not‑
ed lower levels of ApoE in ApoE4 allele carriers (Arrifa‑
no et al., 2018). In addition to lower levels of ApoE and 
diminished detoxification capability, ApoE4 may exert 
its deleterious effects through domain interaction. In 
particular, this interaction may be related to the car‑
boxyl and amino terminal domains which lead to pro‑
duction of neurotoxic fragments, and subsequently, mi‑
tochondrial dysfunction, cytoskeletal alterations, and 
tau phosphorylation (Mahley, 2016). 
Glutathione
Glutathione is the most important endogenous an‑
tioxidant, which is thought to be due to its free sulfhy‑
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dryl group (Coles and Kadlubar, 2003). Recent evidence 
supports the role of oxidative stress in the etiology of 
ASD. One important study found low levels of glutathi‑
one and increased levels of oxidized glutathione in ASD 
(James et al., 2004). Others studies have documented an 
increased prevalence of genetic polymorphisms that 
limit the effectiveness of glutathione mediated detoxifi‑
cation in ASD (Westphal et al., 2000; Buyske et al., 2006; 
Ming et al., 2010; Yochum et al., 2010; Rahbar et al., 
2015). Together, these studies provide additional insight 
into oxidative mechanisms of ASD etiology. Glutathione 
plays a major role in defense against mercury toxicity 
(Cookson and Pentreath, 1996; Tokumoto et al., 2018). 
Different combinations of glutathione‑related genes 
may be associated with ASD, even when the same genes 
are not individually related to ASD (Rahbar et al., 2015). 
Fetal double jeopardy
The above genetic and environmental factors lead 
to a proposed hypothesis that, to our knowledge, has 
not been previously articulated in the medical litera‑
ture. This hypothesis accounts for individually specif‑
ic fetal and infant vulnerability to mercury exposure, 
through maternal and paternal genetics combined with 
environmental exposure. Maternal genetic factors that 
increase risk of mercury toxicity would logically result 
in elevated in utero/fetal levels of mercury exposure. 
An additional role is played by the fetus’s own genetic 
status, half of which is derived from maternal inheri‑
tance. Thus, the role of paternal genetics would be to 
increase or decrease vulnerability to mercury toxicity 
through impacting the fetal genome. Fetal and infant 
genetics determine the degree of toxicity derived from 
gestational and postpartum mercury exposure. The fe‑
tus or infant, therefore, is exposed to maternal genetic 
risks in two ways: 
1) Maternally derived in utero mercury exposure relat‑
ed to maternal genetics and the mother’s exposure 
to mercury during and prior to pregnancy.
2) Through the fetus’s own maternally and paternally 
derived genetic makeup. Thus, the fetus or infant is 
exposed to paternal genetic risk only through the 
inheritance of genes from the father. These factors 
explain the observation that maternal ASD traits 
carry more risk to the child than paternal ASD traits.
The fetal double jeopardy hypothesis
The fetus accumulates an amount of mercury, and 
the amount depends on the genetics of the mother in 
combination with the fetus’s own genetics, as well as, 
maternal exposure to mercury prior to and during the 
pregnancy. It is the fetus or infant’s own genetic char‑
acteristics – that are derived from maternal and pater‑
nal inheritance – that determine how the child handles 
the mercury load to which he/she is exposed. In the 
post‑partum period and extending throughout infancy 
and early childhood, there is additional mercury ex‑
posure through vaccines, food, and potentially other 
exposures. Eventually, a threshold may be crossed that 
results in the neurologic manifestations that we recog‑
nize as ASD.
Epigenetics
Modifications of DNA comprising the genome are 
required for the myriad types of cells in an individual 
to perform their varied functions. A skin cell needs to 
have characteristics distinct from a brain cell, for in‑
stance. These DNA modifications fall into a recently de‑
fined category called “epigenetics”. DNA modifications 
can include DNA methylation, histone modifications, 
microRNA, and other changes. Identical twin studies in 
ASD strongly implicate epigenetic mechanisms, based on 
evidence that genetically identical twins are not univer‑
sally concordant in expression of ASD traits (Hu, 2013).
MicroRNA
MicroRNA (miRNA) are an emerging feature of epi‑
genetic relationships in ASD. MiRNA are non‑coding 
segments of RNA, and about 22 base pairs in length. 
MiRNA are a means of controlling gene expression, by 
preventing transcription of specific proteins/genes. 
Estimates suggest that over 60% of all human genes are 
subject to miRNA regulation, and each miRNA has doz‑
ens to hundreds of potential targets (Ander et al., 2015). 
Recent findings demonstrate the relevance of miRNA to 
long‑term memory formation, cognition, neuronal de‑
velopment, and plasticity, resulting in potentially pro‑
found impacts on brain function (Butler et al., 2016). 
Recent studies have found associations between ab‑
normal miRNAs and ASD. In a 2008 report, nine miR‑
NAs were found to be expressed at significantly differ‑
ent levels in post mortem cerebellar tissue from ASD 
as compared with normal control tissue. The genes 
targeted by these miRNAs are known genetic causes 
of ASD (Abu‑Elneel et al., 2008). In another post mor‑
tem tissue analysis, six specific miRNAs were found to 
be expressed at different levels in ASD compared with 
control samples (Ander et al., 2015). Several other stud‑
ies have identified miRNAs associated with ASD (Ghah‑
ramani Seno et al., 2011; Mundalil Vasu et al., 2014; 
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Ander et al., 2015; Hicks et al., 2016; Wu et al., 2016; 
Jyonouchi et al., 2017; Schumann et al., 2017; Vaccaro et 
al., 2018; Yu et al., 2018). Of note, the genes targeted by 
these ASD‑associated miRNAs play a key role in a range 
of ASD‑related functions, including but not limited to: 
social and language behavioral dysfunctions, TGF‑beta 
signaling, regulation of the actin cytoskeleton, oxida‑
tive phosphorylation, focal adhesion, mTOR signaling, 
ASD sexual dimorphism, neuronal plasticity, and neu‑
ronal development. 
The diagnosis of ASD is often hampered by lack 
of useful measurable markers. MiRNA detection may 
aid in establishing a diagnosis of ASD. One particular 
miRNA shows promise as a serum biomarker for ASD 
(Cirnigliaro et al., 2017). A salivary miRNA evaluation 
appears effective as a non‑invasive screening method 
for markers for ASD (Hicks et al., 2016). 
Together, it is clear that the accumulation of miRNA 
findings in association with ASD has been substantial 
over the past several years. The gene targets of the 
ASD‑associated miRNAs add support to prevailing con‑
cepts of the pathophysiology of ASD. The unanswered, 
and generally unasked question is ‑ what is the reason 
that these miRNAs exist? Are these ASD‑associated 
miRNAs a root cause of the neurologic manifestations 
of ASD, or do they reflect a response to another, more 
fundamental cause of ASD? 
Environmental factors have a major effect on epi‑
genetic modifications. These modifications often allow 
for adaptation to these environmental factors, and the 
modifications tend to be inherited (Feinberg, 2018). For 
instance, one study showed that mercury exposure in‑
duced behavioral changes in zebrafish, and these be‑
havioral changes were subsequently inherited by off‑
spring who lacked direct mercury exposure (Napier et 
al., 2016). Other characteristic epigenetic modifications 
have been reported in response to toxic exposures, in‑
cluding mercury (Basu et al., 2014). In 2015, Bakulski et 
al. reported cord blood epigenetic changes in associa‑
tion with mercury exposure. In another 2015 study, epi‑
genetic changes in paternal sperm were reportedly as‑
sociated with increased ASD risk in offspring (Feinberg 
et al., 2015). Thus, miRNA abnormalities may be related 
to exposure to toxins, including mercury (Li et al., 2015; 
Sanders et al., 2015). The finding of epigenetic changes 
in various diseases and exposures suggests that epigen‑
etic science will be a valuable research tool in under‑
standing the etiology of challenging diseases such as 
ASD. Utilizing epigenetic methods to seek evidence for 
toxic exposures in ASD cohorts may produce even more 
evidence for a link between the two variables. Bakulski 
and Fallin (2014) stated that “epigenetics may repre‑
sent a mechanistic link between environmental expo‑
sures, or genetics, and many common diseases”.
Vaccines and ASD
For over twenty years, mercury from vaccines has 
been suspected to play a causal role in ASD. The transi‑
tion from a normal toddler or young child to one that is 
impaired, often to a severe degree, is heartbreaking to 
parents. If that child has recently been vaccinated, es‑
pecially with vaccines containing the preservative thi‑
merosal, the natural tendency for parents is to blame 
the vaccines. Thimerosal contains mercury in the form 
of ethyl‑mercury. Fortunately, thimerosal has largely 
been removed from pediatric vaccines, although it re‑
mains in some multidose vials.
On the other hand, medical professionals involved 
in public health recognize the unparalleled benefit 
that vaccines have provided in preventing dangerous 
illnesses, many of which have fortunately faded in our 
collective memory. The capability of preventing a vari‑
ety of infectious diseases via vaccination ranks as one 
of the most significant achievements in medicine. The 
success in vanquishing severe diseases, which were 
sources of considerable morbidity and mortality, has 
led to appropriate enthusiasm in applying the expertise 
gained in vaccine development and utilization to ever 
more diseases. An increasing numbers of vaccinations, 
particularly in children, have occurred at a time when 
ASD incidence and prevalence have increased, for rea‑
sons unknown. It is not surprising that some concerned 
individuals have suspected that vaccinations might be 
causally related to the increasing occurrence of ASD.
Vaccines and other medicines in the past have con‑
tained mercury in the form of ethyl mercury, a constitu‑
ent of thimerosal and used as preservative. Compounds 
of mercury are known for being effective anti‑bacteri‑
al agents. Multiple dose vials of vaccine are the most 
likely form of vaccines to contain thimerosal, since in‑
advertent introduction of microbes into the vial when 
withdrawing a vaccine dose might contaminate the 
other doses remaining in the vial. Potential mercury 
exposure, especially in children who are more vulnera‑
ble to associated neurotoxicity, has led to concerns that 
mercury in the vaccines could be causing neurodegen‑
erative diseases. This concern has led to the removal of 
mercury from most vaccines and other medicines.
Multiple peer reviewed manuscripts have been pub‑
lished regarding the potential connection between 
vaccinations and neurodevelopmental disease. Many 
of these research papers support the potential toxicity 
of mercury in vaccines (Makani et al., 2002; Baskin et 
al., 2003; Burbacher et al., 2005; Geier and Geier 2003; 
2006a; 2006b; 2007; Humphrey et al., 2005, James et al., 
2005; Yel et al., 2005; Young et al., 2008; Geier et al., 
2009; Gallagher and Goodman 2010). In a 2003 report, 
the Vaccine Adverse Events Reporting System (VAERS) 
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database demonstrated a marked increase in risk of 
neurodevelopmental disorders in children who re‑
ceived thimerosal containing DTaP vaccines compared 
with thimerosal‑free but otherwise similar vaccines. 
The relative risk of ASD with the mercury containing 
vaccines was 6.0. The relative risk of mental retarda‑
tion was 6.1 (Geier and Geier, 2003).
Other publications report ostensibly reassuring safety 
data regarding the risk of serious neurologic consequenc‑
es from vaccinations in general, and thimerosal in partic‑
ular. However, weak neurotoxicity associations with mer‑
cury in vaccines were reported in these studies, noting 
problems with attention, executive functioning, speech 
articulation, and motor tics in boys. Despite the reas‑
surance of the authors of these studies, refuting the vac‑
cine‑ASD connection, the association of thimerosal with 
neurologic symptoms, albeit mild ones, is less comfort‑
ing to others (Stehr‑Green et al., 2003; Verstraeten et al., 
2003; DeStefano, 2007; Thompson et al., 2007, McMahon 
et al., 2008; McGuinness 2015; Gogoi and Chatterjee 2016).
The authors of these papers expressing differing 
conclusions are likely sincere scientists, truly believing 
the assessments they have articulated. One clear fact 
persists: there is not unanimity of opinion on whether 
a vaccine might contribute to ASD risk. How can we rec‑
oncile these disparate findings? Genetics may hold an 
answer. The previously noted genetic factors involved 
in the risk of mercury toxicity were not considered in 
vaccine studies, given that the genetic factors were 
more recently reported. These genetic (or genomic) 
factors may be part of the reason for the conflicting 
conclusions of vaccine safety studies.
Of course, the above discussion of vaccine and thi‑
merosal risk is rendered nearly moot by the removal of 
thimerosal from almost all vaccines. On the CDC website, 
the vaccine summary PDF notes that, to‑date, thimero‑
sal is present only in a limited number of vaccines: Flu‑
virin, meningococcal vaccine, Td (Mass Biologics), and 
in multi‑dose vials of the influenza vaccine. Of note, the 
influenza vaccine is recommended for pregnant women, 
infants, and children. Thimerosal continues to be pres‑
ent in childhood vaccines that are used in developing 
countries (Sykes et al., 2014). The risk of inducing thi‑
merosal‑mediated neurologic toxicity persists, although 
removal of mercury from many vaccines has reduced 
that risk. It is incumbent on parents and physicians to 
keep that risk low through awareness and avoidance of 
mercury‑containing vaccines, when possible. 
ASD etiology
Progress in prevention and treatment of ASD has 
been rendered limited or impossible by the lack of fun‑
damental understanding of the etiology. The factors 
discussed in this paper point to a hypothesis that is 
consistent with the facts as currently understood and 
accounts for the clinical manifestations, heritability, 
genetics, and clinical course of ASD.
The mercury hypothesis of autism  
spectrum disorder
To summarize the data and hypotheses presented 
above; when present in excess in the brain, mercury 
causes (via free radical and oxidative reactions) (Sara‑
fian et al., 1994; Shenker et al., 2002) brain inflamma‑
tion (Lee et al., 2010; Theoharides and Zhang 2011; 
Theoharides et al., 2016) and mitochondrial dysfunc‑
tion (Smith et al., 2012). Inflammation and mitochon‑
drial dysfunction, in turn, lead to dysfunction of the 
brain to various degrees, manifesting as the clinical 
picture of ASD. Children are at highest risk of develop‑
ing ASD due to the increased vulnerability of the devel‑
oping brain (Andreoli and Sprovieri, 2017).
Genetic factors impact the potential of each individ‑
ual to experience toxicity from a given level of mercu‑
ry exposure, and the consequent likelihood of clinical 
brain dysfunction (Goodrich et al., 2011; Parajuli et al., 
2016). These genetic influences impact the degree to 
which a given amount of mercury will be absorbed into 
the body, and/or how effectively it will be eliminated or 
metabolized, if at all. Genetic factors can also modulate 
the degree of damage from a given amount of mercury 
in that individual. The “double jeopardy” highlights the 
prenatal impact of maternal gene‑mediated mercury 
metabolism and the fetal innate genetic mercury resis‑
tance or vulnerability. This combination of factors cre‑
ates a unique pattern of inheritance that is difficult to 
explain through other mechanisms. The prenatal period 
is particularly important, due to the increased risk of the 
developing fetal brain to damage from mercury (Bjork‑
lund et al., 2017). In the postpartum period, the infant’s 
own mercury management takes over and is completely 
dependent on the infant’s own genetics ‑ as inherited 
from maternal and paternal sources. The developing in‑
fant brain only very gradually becomes less at risk from 
mercury exposure, eventually reaching the adult level 
of vulnerability as adulthood approaches. Therefore, 
the risk from mercury exposure continues throughout 
infancy and onward. The source of these exposures may 
include dietary components (largely seafood), vaccines 
and medicines, dental amalgams, and random environ‑
mental exposures (for e.g., a broken mercury thermom‑
eter, or broken florescent or CFL light bulb.)
There are challenges unique to pursuing the po‑
tential role of mercury in neurologic disease. For one, 
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mercury impairs enzyme functioning which has the 
effect of limiting its own excretion. In addition, urine 
mercury levels are unreliable indicators of mercury 
levels in the body (Ely, 2001). Even hair levels of mer‑
cury are not reliable, being low at times when they 
are expected to be high. Mercury also exists in differ‑
ent phases in the body. Mercury from fish sources is 
in the form of methyl mercury whereas vaccines may 
contain ethyl mercury. Methyl mercury has a blood 
half‑life of about 60 days (Smith and Farris, 1996) 
whereas the blood half‑life of ethyl mercury is about 
10 days or fewer (Dorea et al., 2013). In the brain, 
however, methyl and ethyl mercury are partially con‑
verted to the inorganic state, which has a half‑life 
measured in several decades. This means that, once 
mercury reaches the brain, it is essentially there per‑
manently. There is no assay to determine how much 
inorganic mercury is in a living person’s brain (Bjork‑
man et al., 2007). There is speculation about the rel‑
ative fates of methyl and ethyl mercury. The shorter 
blood half‑life of ethyl mercury may be related to its 
more rapid conversion to inorganic mercury in the 
brain and other tissues (Harry et al., 2004). Given that 
methyl and ethyl mercury are cleared from the blood 
in a relatively short time, and that inorganic brain 
mercury is not measurable, it is apparent that longer 
term mercury exposures are much more difficult to 
ascertain (Mutter et al., 2010).
Why has an association between the toxic effects 
of mercury and neurodevelopmental disease not been 
previously recognized? One reason may be the hetero‑
geneous response to a given level of mercury in differ‑
ent people. As previously noted, genetics may render 
some persons relatively resistant to levels of mercury 
that, in other persons, are quite toxic.
Another reason for resistance to recognizing subtle 
mercury toxicity is the economic consequence of that 
recognition. Dental amalgams are fortunately rarely 
used in the United States, but the removal of those 
already in place would entail much expense. More 
concerning is the mercury emitted into the environ‑
ment through fossil fuel burning power plants, some 
types of gold mining, cement production, and other 
industrial processes. In addition, some vaccines may 
still contain low levels of mercury and seafood often 
contains significant amounts. The elimination of mer‑
cury contamination of our air, water, medicine, and 
food would entail considerable expense, and require 
decades or longer to substantially accomplish. A high 
level of evidence will be required for the societies and 
nations of the world to accept that such a huge effort 
is needed and/or economically responsible.
Perhaps the most useful approach at this time for 
determining the role, if any, that mercury plays in 
the pathogenesis of ASD, would be through genomics 
and the related field of epigenetics. It is well within 
the grasp of current research methods to detect tar‑
get mutations or epigenetic modifications involved 
in impaired mercury handling. Should studies of ASD 
patients show increased numbers of such mutations 
or modifications compared with controls, that would 
constitute strong evidence for a causal role of mercu‑
ry in the pathogenesis of ASD. The remarkable Casa 
Pia study, discussed previously in this paper, did in 
fact show an association between mercury and mild 
cognitive impairment in apparently normal chil‑
dren who had specific genetic polymorphisms impli‑
cated in mercury handling (Woods et al., 2014). Re‑
searchers are identifying a rapidly increasing number 
of such mutations in genes that modify the body’s 
handling of mercury (Andreoli and Sprovieri, 2017). 
Evidence of increased mercury handling mutations or 
certain epigenetic characteristics in individuals with 
ASD and, more importantly, their mothers, would im‑
ply a causal role for mercury in ASD. Given the vul‑
nerability of the fetal brain to low levels of mercu‑
ry, a maternal genomic/epigenetic study is clearly 
needed. The relative strength of each of the proposed 
mutations or epigenetic modifications would likely 
vary, thereby complicating the interpretation of such 
findings. There is already evidence linking genetic 
variation in one mercury handling polymorphism ‑ 
the ApoE system ‑ to Alzheimer’s disease and ASD. In 
particular, carriers of the ApoE4 allele demonstrate 
increased propensity for both mercury toxicity and 
neurodevelopmental disability, including Alzheimer’s 
disease and ASD (Strittmatter et al., 1993; Godfrey et 
al., 2003; Ng et al., 2013; 2015). The potency of ApoE4 
in expressing these effects may overshadow lesser 
mutations.
Finally, a comprehensive review found that, as of 
2016, there were 91 original studies in humans that 
examined the potential relationship between mercury 
and ASD. Of those 91 studies, 74% found a relationship 
between mercury exposure and ASD, indicating that 
mercury exposure may play a causal and/or contribu‑
tory role in ASD (Kern et al., 2016). 
CONCLUSION
Mercury is a complex element and is unique among 
the toxic heavy metals in that it exists in three phases 
in the body (i.e., elemental, inorganic, and organic). 
The impact of mercury on its own means of excretion 
complicates our attempts to understand the subtleties 
of its impact on human pathophysiology. Recent ad‑
vances in genomics and epigenetics offer a previously 
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unavailable means to determine if mercury plays a role 
in a number of human diseases.
ASD has clinical and pathophysiological character‑
istics that are strongly suggestive of mercury toxicity. 
At present, ASD lacks a broadly accepted or identified 
etiology. The data presented in this paper are consis‑
tent with the notion that the etiology of ASD arises 
during the gestational period and beyond as a manifes‑
tation of mercury toxicity. Although beyond the scope 
of this paper, other heavy metals and toxic exposures 
that have similar toxic manifestations may eventually 
be incorporated into this hypothesis.
Additional research is needed to understand the po‑
tential role of mercury in ASD. Genomic and epigenetic 
analyses should identify populations that are vulnera‑
ble to mercury toxicity. These approaches may hold the 
long‑awaited key that allows for the identification of 
a fundamental etiology of ASD, and potentially, a broad 
range of neurodevelopmental diseases. The prospect of 
finally being able to finally prevent and treat such dis‑
eases is tantalizing, indeed. 
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